The Rise of Cell and Gene Therapy CRO
Over 500 cell and gene therapy candidates are being investigated in different stages of clinical development across various geographies. In fact, in the past five years alone, more than 1,000 clinical trials, that are currently active, were initiated to evaluate the potential of these cell and gene therapies across multiple therapeutic indications. Due to several development challenges, such as fragile nature of cells being used, safety and efficacy issues, laborious procedures for conducting clinical studies, complex regulatory framework and exorbitant costs, it is difficult for the companies with limited expertise and finances to successfully develop these therapies in-house. The aforementioned challenges have led several players to outsource a significant part of their clinical stage research to capable cell and gene therapy CRO, which claim to offer cost-efficient solutions as well as intellectual and operational expertise.
Over 70 cell and gene therapy CROs provide a variety of early and late stage product development-related services to cell and gene therapy developers
Primarily based in the US and EU, the key innovation hubs, cell and gene therapy CRO of varying sizes are offering support at both preclinical and clinical stages of product development
Cell therapies is one of the main focus areas; specifically, stem cell therapy has emerged as relatively more popular among small and mid-sized CROs
Over 1,000 active clinical trials, focused on cell therapies, have been registered across the globe in the last five years, highlighting the increasing demand for contract service providers
Companies involved in this domain are steadily expanding their capabilities to strengthen their service portfolio and align with contemporary industry benchmarks
Several partnerships over the last six years indicate the rising interest in this domain; players are actively entering into collaborations focused on diverse types of cell therapies
The cell and gene therapy CRO market is projected to grow at a steady pace of 8.9% annually; the opportunity is expected to be well distributed across different type of therapies, various regions and therapeutic areas
To learn more, please click Cell and Gene Therapy CRO Market. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com. You can also download the SAMPLE REPORT on cell and gene therapy CRO by Roots Analysis.
Our Social Media Platform
Gene Therapy Pipeline Update: Adverum Biotechnologies Doses First Patient for Wet AMD
Cell Therapy Manufacturing: The $ 8 Billion+ Growth Opportunity
Gene Therapy Pipeline Update: Orchard Therapeutics Presents Data on Metachromatic Leukodystrophy
About Author
Arun_Gupta
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.